News | Stent Grafts | July 10, 2019

First U.S. Patient Receives Gore Tag Conformable Thoracic Stent Graft With Active Control

Data shows 100 percent successful deployment and no fractures at 30-day follow-up in European registry

First U.S. Patient Receives Gore Tag Conformable Thoracic Stent Graft With Active Control

July 10, 2019 — W. L. Gore & Associates Inc. (Gore) announced the first U.S. implant of the Gore Tag Conformable Thoracic Stent Graft with Active Control System. The successful procedure was performed by William Jordan, M.D., chief of the Division of Vascular Surgery and Bradley Leshnower, M.D., cardiothoracic surgeon, at the Emory University School of Medicine in Atlanta. This first case follows the recent U.S. Food and Drug Administration (FDA) approval for this new device.

The Gore Tag Conformable Thoracic Stent Graft with Active Control System delivers new levels of control in the endovascular repair of aneurysms, transections and Type B dissections of the thoracic aorta, according to the company. A key feature of this device is a delivery system that provides controlled, two-stage deployment, with primary deployment to an intermediate diameter and a secondary deployment to full diameter. In addition to the staged deployment, a lockwire keeps the stent graft attached to the catheter through the procedure, enhancing the physician’s control. The device also features a full 2 French reduction in profile over previous designs across 10 device sizes.

“The two-stage deployment provided by the Gore Tag Conformable Thoracic Stent Graft with Active Control System allows for continuous blood flow, and it gives me multiple opportunities to visualize and refine graft placement for accurate placement and peace of mind,” said Jordan. “The new delivery system gives me added precision in placement and angulation so I can take full advantage of the conformability of the Gore device and confidently provide a minimally-invasive solution to more patients, even in patients with complex anatomy.”

The device received CE Mark in 2017. At 30-day follow-up, it demonstrated 100 percent successful deployment and zero type IA or type III endoleaks, fractures, device compressions or ruptures, according to real-world data from the post-market European observational, single-arm SURPASS registry. No device-related issues were reported by 98.4 percent of registry participants, and 97.2 percent of registry subjects were reported free from serious access complications. Further, 98.4 percent of registry participants reported improved proximal wall apposition at procedural completion, and 92.9 percent reported no rapid pacing was used.

For more information: www.gore.com

Related Content

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav